Sanofi 3Q Profit, Sales Grew; Raises 2021 Business EPS View

By Cecilia Butini

Sanofi SA on Thursday posted higher net profit and sales for the third quarter compared with the previous year, and raised its guidance for business earnings per share for the full year.

The French pharma major posted net profit of 2.32 billion euros ($2.69 billion) up from EUR1.95 billion in the same quarter a year prior, on sales which grew to EUR10.43 billion from EUR9.48 billion in 2020.

The company said sales growth was driven by the strong performance of bestselling drug Dupixent, record sales of vaccines, and business momentum in its consumer healthcare business.

Business net income--a metric which Sanofi uses to indicate income without certain one-off items--was EUR2.74 billion, an increase from EUR2.30 billion in the same quarter the previous year.

Sanofi raised its business EPS guidance for the year and now expects the metric to grow around 14% at constant exchange rates, barring unforeseen major adverse events. The company had previously expected 12% business EPS growth at constant exchange rates.

Write to Cecilia Butini at [e-mail]

(END) Dow Jones Newswires

October 28, 2021 01:50 ET (05:50 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.